Literature DB >> 12742657

Glucocorticoid involvement in suppression of NK activity following surgery in rats.

Guy Shakhar1, Barak Blumenfeld.   

Abstract

We studied plasma factors mediating suppression of NK activity (NKA) following surgery. Plasma from operated rats suppressed NKA of splenocytes, leukocytes, and purified natural killer (NK) cells, and charcoal stripping nullified suppression. The glucocorticoid antagonist mifepristone prevented suppression, whereas blockers of reactive oxygen metabolites, opioids, catecholamines, prostaglandin-E2, and histamine did not. NKA dropped as corticosterone levels peaked postoperatively, and administration of relevant doses of corticosterone suppressed NKA. Inhibition of glucocorticoid synthesis prevented plasma from suppressing NKA but merely attenuated NKA suppression in operated rats. Thus, postoperative concentrations of corticosterone can directly suppress NKA but additional factors probably act in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742657     DOI: 10.1016/s0165-5728(03)00118-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  Stress and skin leukocyte trafficking as a dual-stage process.

Authors:  Elad Neeman; Lee Shaashua; Marganit Benish; Gayle G Page; Oded Zmora; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2011-09-19       Impact factor: 7.217

2.  Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression.

Authors:  Roi Avraham; Marganit Benish; Shelly Inbar; Inbal Bartal; Ella Rosenne; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2010-03-31       Impact factor: 7.217

3.  In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins.

Authors:  Ella Rosenne; Liat Sorski; Lee Shaashua; Elad Neeman; Pini Matzner; Ben Levi; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2013-12-12       Impact factor: 7.217

4.  Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration.

Authors:  Mahesh N Samtani; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2005-04       Impact factor: 1.627

Review 5.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

Review 6.  Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement.

Authors:  Elad Neeman; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2012-04-04       Impact factor: 7.217

7.  Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition.

Authors:  Liat Sorski; Rivka Melamed; Pini Matzner; Hagar Lavon; Lee Shaashua; Ella Rosenne; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2016-05-25       Impact factor: 7.217

8.  CpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: potential implications for clinical use.

Authors:  Yael Goldfarb; Ben Levi; Liat Sorski; Dan Frenkel; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2010-07-23       Impact factor: 7.217

9.  Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue.

Authors:  Manuela Banciu; Josbert M Metselaar; Raymond M Schiffelers; Gert Storm
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

10.  PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity.

Authors:  G Meron; Y Tishler; L Shaashua; E Rosenne; B Levi; R Melamed; N Gotlieb; P Matzner; L Sorski; S Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2012-11-12       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.